Tests LN-145 cell therapy for metastatic non-small-cell lung cancer
Tests LN-145, a patient's own immune cells, in adults with advanced lung cancer.
Plain-language title generated from the registry record
Registry title: Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Key facts
- Where
- A Coruña, Barcelona, Castello De La Plana, Córdoba, Madrid, Málaga, Pamplona, Salamanca, Sevilla, and Valencia, SpainSee the 15 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT04614103, who can take part
Where in Spain
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpainNo longer taking part
- Hospital Clinic de BarcelonaBarcelona, SpainNo longer taking part
- Instituto Oncologico Dr. Rosell S.L.Barcelona, SpainNo longer taking part
- Consorcio Hospital General Universitario De ValenciaCastello De La Plana, SpainNo longer taking part
- Hospital Universitario Reina SofiaCórdoba, SpainNo longer taking part
- Clinica Universidad de NavarraMadrid, SpainNo longer taking part
- Hospital Universitario 12 de OctubreMadrid, SpainNo longer taking part
- Hospital Universitario HM SanchinarroMadrid, SpainNo longer taking part
- Hospital Universitario La PazMadrid, SpainNo longer taking part
- Hospital Universitario Ramón y CajalMadrid, SpainNo longer taking part
- Hospital Universitario Regional de MálagaMálaga, SpainNo longer taking part
- Clínica Universidad de navarraPamplona, SpainNo longer taking part
- Hospital Universitario De SalamancaSalamanca, SpainNo longer taking part
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainNo longer taking part
- Hospital Clinico Universitario de ValenciaValencia, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Iovance Biotherapeutics, Inc.
- Trial code
- NCT04614103EU 2024-510778-26-00
- Record updated
- 26 June 2026
- Original description
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancerRead full original descriptionShow less
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Inclusion: Patients who are over 70 years of age may be allowed to enroll after discussion with the Medical Monitor; Have historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS1 genomic alterations; For patients who have actionable mutations (other than EGFR, ALK, or ROS1 genomic alterations), 1 additional line of therapy with the appropriate health authority approved targeted therapy is required; Patients must have documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and platinum-based chemotherapy ± bevacizumab. No more than 1 prior line is allowed if ICI and platinum-based chemotherapy were administered concurrently and no more than 2 prior lines are allowed for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines; LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination and meet all eligibility criteria except documented disease progression. These patients must intend to receive TIL therapy after disease progression; Prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy, will count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy; At least 1 resectable lesion for TIL production and at least one remaining measurable lesion, as defined by RECIST v1.1; Have adequate organ function; LVEF > 45%, NYHA Class 1; Have adequate pulmonary function; ECOG performance status of 0 or 1; Patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy.
Exclusion: Patients who have had allogeneic organ transplant or prior cell therapy within the past 20 years; Patients who are on systemic steroid therapy ≥ 10 mg/day of prednisone or equivalent; Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment; Patients who have had another primary malignancy within the previous 3 years; Patients who have EGFR, ALK or ROS1 driver mutations; Patients who have symptomatic, untreated brain metastases; Patients who have any form of primary immunodeficiency; Participation in another interventional clinical study within 21 days.